Will the Phase 2 trial "A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma." reach primary completion on or before Oct 28, 2026?

Resolves Yes if ClinicalTrials.gov record NCT05747729 (Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) shows an actual primary completion date on or before Oct 28, 2026. Registered date at generation: Oct 28, 2026.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Oct 28, 2026, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.